Insider transactions

David W Gryska

CIK 1202335 · Executive Vice President, CFO · last filed 2026-10-05

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$1.93M
Companies
12
Total Filings
119
Lifetime Open-Market Net
-$23.62M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

SGEN price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
749 N MARY AVE
SUNNYVALE, CA 94085
Related Filers
CELGENE CORP /DE/ — 22 joint filings, latest 2010-07-15
INCYTE CORP — 18 joint filings, latest 2018-07-18
PDL BIOPHARMA, INC. — 16 joint filings, latest 2020-12-31
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count in each company: direct shares plus every indirect holder (trusts, LLCs, partnerships, family members) on the latest Form 4 that lists them. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CELC Director 893 $64.37 $57.5K $0 1 2026-10-05
Forte Biosciences, Inc. (FBRX) Delisted Director 0 $76.99 $0 $0 7 2026-08-27
DFTX Director 19,900 $32.08 $638.4K $0 1 2026-06-15
Definium Therapeutics, Inc. (MNMD) Delisted Director 19,851 $15.00 $297.8K $38.9K 5 2025-06-16
Seagen Inc. (SGEN) Delisted Director 0 $228.74 $0 -$9.71M 42 2023-12-15
AERIE PHARMACEUTICALS INC (AERI) Delisted Director 0 $15.25 $0 $0 7 2022-11-21
GW PHARMACEUTICALS PLC (GWPH) Delisted Director — $218.96 — $0 2 2021-02-24
PDL BIOPHARMA, INC. (PDLI) Delisted Director 1,387 — — -$925.8K 14 2020-12-31
INCY Executive Vice President, CFO 10,235 $120.97 $1.24M -$9.18M 17 2018-07-18
HYPERION THERAPEUTICS INC (HPTX) Delisted Director — — — $0 1 2013-05-01
CELGENE CORP /DE/ (CELG) Delisted Chief Financial Officer 7,526 — — -$3.84M 20 2010-07-15
COTHERIX INC (CTRX) Delisted Director — — — $0 1 2007-01-10

Holdings By Holder

Who holds the shares on record: the insider directly, and each trust, LLC, partnership or family member reported as an indirect holder on the latest Form 4 that lists them. Holder names come from the filing's footnotes. Rows under No longer reported appeared on earlier filings but not the latest one, usually because the holder was emptied or folded into another; they are not counted in the total.
Symbol Holder Shares Share of Total Reported
AERI Direct 0 — 2022-11-21
By the Gryska Family Trust 0 — 2022-11-21
Total 0
CELG Direct 6,026 80.1% 2010-05-05
401 (k) Plan 1,500 19.9% 2010-05-05
Total 7,526
No longer reported
401(k) Plan 454 — last 2008-11-05

Recent Filings · Page 9 of 12

119 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144, so not all of them end in a sale. Under each notice: the role the filer ticked on it, and whether a sale followed (a Form 4 sale within 30 days, or a sale listed on a later notice).
Filed Symbol Action Net Shares Net $ Link
2013-09-05 Seagen Inc. (SGEN) Delisted Mixed — -$324.0K EDGAR
2013-05-21 Seagen Inc. (SGEN) Delisted Grant (A) +3,500 $0 EDGAR
2013-05-01 HYPERION THERAPEUTICS INC (HPTX) Delisted Grant (A) — $0 EDGAR
2013-02-27 Seagen Inc. (SGEN) Delisted Mixed — -$204.8K EDGAR
2012-08-14 Seagen Inc. (SGEN) Delisted Exer (M) +7,500 $37.5K EDGAR
2012-06-06 Seagen Inc. (SGEN) Delisted Sell (S) −8,000 -$158.0K EDGAR
2012-05-22 Seagen Inc. (SGEN) Delisted Grant (A) — $0 EDGAR
2011-12-16 Seagen Inc. (SGEN) Delisted Exer (M) +4,500 $22.5K EDGAR
2011-12-13 Seagen Inc. (SGEN) Delisted Sell (S) −10,000 -$180.9K EDGAR
2011-05-24 Seagen Inc. (SGEN) Delisted Grant (A) — $0 EDGAR
Showing 81–90 of 119
Page 9 of 12
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).